| Cited in | International search | Type: | Non-patent literature | Publication information: | [YD] SORIANO ET AL.: "Abstract: The use of a fidaxomicin chaser as effective salvage therapy for vancomycin-refractory, recurrent Clostridium difficile infections (IDWeek 2013)", 5 October 2013 (2013-10-05), XP055182724, Retrieved from the Internet [retrieved on 20150414] [YD] 1-21 * the whole document * | Type: | Non-patent literature | Publication information: | [YD] MELINDA M SORIANO ET AL: "The Use of a Fidaxomicin Taper/Pulsed Chaser as Effective Salvage Therapy for Vancomycin-Refractory, Recurrent Clostridium difficile Infections", 5 October 2013 (2013-10-05), XP055182720, Retrieved from the Internet [retrieved on 20150414] | Type: | Non-patent literature | Publication information: | [YD] C. CHILTON ET AL: "2013: K-336. Comparison of Extended Duration Fidaxomicin Dosing Regimens for Treatment of Clostridium difficile Infection (CDI) in an in vitro Gut Model", September 2013 (2013-09-01), XP055182841, Retrieved from the Internet [retrieved on 20150414] [YD] 1-21 * the whole document * | Type: | Non-patent literature | Publication information: | [YD] C. H. CHILTON ET AL: "Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 69, no. 2, 3 September 2013 (2013-09-03), pages 451 - 462, XP055182651, ISSN: 0305-7453, DOI: 10.1093/jac/dkt347 [YD] 1-21 * abstract * | DOI: | http://dx.doi.org/10.1093/jac/dkt347 | Type: | Non-patent literature | Publication information: | [A] S. JOHNSON ET AL: "Fidaxomicin "Chaser" Regimen Following Vancomycin for Patients With Multiple Clostridium difficile Recurrences", CLINICAL INFECTIOUS DISEASES, vol. 56, no. 2, 28 September 2012 (2012-09-28), pages 309 - 310, XP055182579, ISSN: 1058-4838, DOI: 10.1093/cid/cis833 [A] 1-21 * page 2, column r * | DOI: | http://dx.doi.org/10.1093/cid/cis833 | Type: | Non-patent literature | Publication information: | [A] THER ADV: "Therapeutic Advances in Gastroenterology Review", 2012, pages 395 - 402, XP055182638, Retrieved from the Internet [A] 1-21 * page 400 * | Type: | Non-patent literature | Publication information: | [Y] G. W. TANNOCK ET AL: "A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin", MICROBIOLOGY, vol. 156, no. 11, 19 August 2010 (2010-08-19), pages 3354 - 3359, XP055182699, ISSN: 1350-0872, DOI: 10.1099/mic.0.042010-0 [Y] 1-21 * page 3358 * | DOI: | http://dx.doi.org/10.1099/mic.0.042010-0 | Type: | Non-patent literature | Publication information: | [Y] T. J. LOUIE ET AL: "Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI", CLINICAL INFECTIOUS DISEASES, vol. 55, no. suppl 2, 2 July 2012 (2012-07-02), pages S132 - S142, XP055205254, ISSN: 1058-4838, DOI: 10.1093/cid/cis338 [Y] 1-21 * page s137 * | DOI: | http://dx.doi.org/10.1093/cid/cis338 | Type: | Non-patent literature | Publication information: | [XP] "Efficacy of tapered fidaxomicin dosing regimens to treat simulated Clostridium difficile infection (CDI) in an in vitro gut model", 14 May 2014 (2014-05-14), XP055182784, Retrieved from the Internet [retrieved on 20150414] [XP] 1-21 * the whole document * | Type: | Non-patent literature | Publication information: | [YP] M. M. SORIANO ET AL: "Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies", OPEN FORUM INFECTIOUS DISEASES, vol. 1, no. 2, 1 August 2014 (2014-08-01), pages ofu069 - ofu069, XP055182559, DOI: 10.1093/ofid/ofu069 [YP] 1-21 * pages 5-6 * | DOI: | http://dx.doi.org/10.1093/ofid/ofu069 | Type: | Non-patent literature | Publication information: | [T] C. H. CHILTON ET AL: "Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 14 June 2015 (2015-06-14), XP055205152, ISSN: 0305-7453, DOI: 10.1093/jac/dkv156 [T] * page 9 * | DOI: | http://dx.doi.org/10.1093/jac/dkv156 | Cited in | by applicant | Type: | Non-patent literature | Publication information: | S. NIU ET AL., CHEMBIOCHEM, vol. 12, 2011, pages 1740 - 1748 [Y] 1-21 * page s137 * | Type: | Non-patent literature | Publication information: | WIEGAND P.N.; NATHWANI D.; WILCOX M.H. ET AL., J. HOSP INFECT, 10 April 2012 (2012-04-10) | Type: | Non-patent literature | Publication information: | GHANTOJI S.S.; SAIL, K.; LAIRSON D.R., J. HOSP. INFECT., vol. 74, 2010, pages 309 - 318 [XP] 1-21 * the whole document * | Type: | Non-patent literature | Publication information: | MCFARLAND LV: "Epidemiology, risk factors and treatments for antibiotic-associated diarrhea", DIG DIS, vol. 16, 1998, pages 292 - 307 [YP] 1-21 * pages 5-6 * | Type: | Non-patent literature | Publication information: | WISTROM J; NORRBY SR; MYHRE E ET AL.: "Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study", J ANTIMICROB CHEMOTHER, vol. 47, 2001, pages 43 - 50 [T] * page 9 * | Type: | Non-patent literature | Publication information: | CROOK ET AL., CLIN. INFECT. DIS., vol. 55, no. 2, 2012, pages 93 - 103 | Type: | Non-patent literature | Publication information: | T. LOUIE ET AL., 22ND EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 31 March 2012 (2012-03-31) | Type: | Non-patent literature | Publication information: | T.J. LOUIE ET AL., CLIN. INFECT. DIS., vol. 55, no. S2, 2012, pages 132 - 142 | Type: | Non-patent literature | Publication information: | TANNOCK, MICROBIOLOGY, vol. 156, 2010, pages 3354 - 3359 | Type: | Non-patent literature | Publication information: | SORIANO ET AL., EXP REV ANTIINFTHER, vol. 1, 2013, pages 767 - 776 | Type: | Non-patent literature | Publication information: | M.M. SORIANO ET AL., ABSTRACT 42591; PRESENTATION NO. 1410; IDWEEK, 5 October 2013 (2013-10-05) | Type: | Non-patent literature | Publication information: | C.H. CHILTON ET AL., J. ANTIMICROBIAL CHEMOTHERAPY ADVANCE ACCESS, September 2013 (2013-09-01) | Type: | Non-patent literature | Publication information: | C.H. CHILTON ET AL., 23RD EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASE, 27 April 2013 (2013-04-27) | Type: | Non-patent literature | Publication information: | MACFARLANE ET AL., MICROBIAL ECOLOGY, vol. 35, 1998, pages 180 - 187 | Type: | Non-patent literature | Publication information: | IUPAC RECOMMENDATIONS 1996, PURE & APPLIED CHEMISTRY, vol. 68, 1996, pages 2193 - 2222 | Type: | Non-patent literature | Publication information: | L. LACHMAN ET AL.: "The Theory and Practice of Industrial Pharmacy", 1986 | Type: | Non-patent literature | Publication information: | "Remington's Pharmaceutical Science", 1990, pages: 1644 | Type: | Non-patent literature | Publication information: | "Remington's Pharmaceutical Sciences", 1990, pages: 1666 | Type: | Non-patent literature | Publication information: | FREEMAN J; O'NEILL FJ; WILCOX MH: "The effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut", J ANTIMICROB CHEMOTHER, vol. 52, 2003, pages 96 - 102 | Type: | Non-patent literature | Publication information: | BAINES SD; FREEMAN J; WILCOX MH: "Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model", J ANTIMICROB CHEMOTHER, vol. 55, 2005, pages 974 - 82 |
